A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Conditions
Sickle Cell Disease · Thalassemia, Beta · Thalassemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, United States
Memorial Sloan Kettering Suffolk - Commack (Consent only), Commack, New York, United States
Memorial Sloan Kettering Westchester (Consent only), Harrison, New York, United States
Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre, New York, United States
Study leads
Maria Cancio, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center